Which cervical screening test should you have? Recommendations against the actual service, the age boundaries, and what three routes cost, 2026

TL;DR The Department of Health's recommendations page still lists three methods side by side, but the Department's own service has used HPV testing as the primary method for women aged 30 to 64 since April 2023; 25 to 29 stays on cytology. Anyone reading only the recommendations page will think all three are still equal at the service level. And one more thing to keep: a normal screening result is not safety — if you have symptoms, see a doctor promptly rather than waiting for the next screen.

---

#Two official pages out of step: the recommendations list three methods, the service moved years ago

The most easily missed point first. The Department of Health's "Screening Target and Recommendations" page still lists three methods side by side for ages 30 to 64: cytology every three years, HPV testing every five years, co-testing every five years.

But the Department's own FAQ page and its press release of 26 October 2025 both state that since April 2023 the Department has adopted HPV testing as the primary screening method for women aged 30 to 64 [Note 1].

Both are official documents and neither is wrong. The three options on the recommendations page are the 2021 recommendation as written; the Department's own service moved in April 2023.

⚠️ The practical consequence is concrete: at a Maternal and Child Health Centre, the default for ages 30 to 64 is HPV testing.

Where the recommendation comes from: the Cancer Coordinating Committee was established in 2001, the Cancer Expert Working Group on Cancer Prevention and Screening under it in 2002, the Group published recommendations on seven common cancers in 2004, and the Cervical Screening Programme launched the same year. In June 2021 the Group revised its recommendations (endorsed at the Committee's 16th meeting on 18 June that year), listing HPV-based screening as an option from age 30 for the first time.

The Group states that it deliberated against the World Health Organization's ten screening principles of Wilson and Jungner, 1968 [Note 2]. Cervical cancer is one of the few cancers genuinely suited to population screening precisely because one of those principles holds for it: the natural history must be adequately understood — it has a viral cause, an identifiable pre-cancerous stage, and it is treatable.

---

#Why is HPV testing not used for 25 to 29? The answer is more than "false positives"

Three pairs of ideas first, because they are the foundation of everything below: screening is not diagnosis (screening is for women without symptoms); positive is not diagnosed (a screening result is a reference only and cannot replace a doctor's professional diagnosis); and HPV infection is not cervical cancer [Note 3].

The third pair needs saying more fully. About 90% of HPV infections clear on their own within two years, and only a small proportion of persistent infections become cancer over 15 to 20 years.

⚠️ But that sentence is conditional in the original: it is about women with normal immune systems. It does not apply to the chronically immunosuppressed.

The two tests look at different things. Cervical cytology (the Pap smear) tests whether cells have changed — it looks at now, so a three-year interval keeps track of change. HPV testing tests the cause, and looks at risk over the next several years.

So why not HPV testing under 30? Because of positive predictive value.

Positive predictive value is the proportion of those testing positive who really have the target lesion. The US National Cancer Institute states that for a given sensitivity and specificity, the lower the prevalence, the lower the positive predictive value and the higher the negative predictive value [Note 4].

Among women aged 25 to 29 HPV infection is common but progression to CIN2+ is very rare, so most of the extra positives are false alarms.

The Government's reason is that because infections in this group are largely transient, HPV testing may lead to unnecessary follow-up tests and medical procedures [Note 5]. The College of Obstetricians and Gynaecologists puts it more concretely: detecting infections that will clear anyway costs anxiety, stigma, discomfort and bleeding at investigation and treatment, and complications such as preterm birth from unnecessary treatment.

There is a cost in figures too: colposcopy referral rates under 30 are 2.3% to 13.1% for HPV-based testing against 1.9% to 4.7% for cytology. A modelling study calculated 30 as the switch point with the best harm-benefit ratio, using colposcopy as a proxy for harms.

But that cost has an officially recognised remedy, and it is written in the same paragraph. The same Group document states that where an HPV-positive result is triaged by cytology, the false-positive rate and the colposcopy referral rate become comparable with cytology, and recommends cytology or HPV 16/18 genotyping as a second-line triage test [Note 6].

So "HPV testing produces more false positives" describes the untriaged approach. The official reason for not making HPV testing the mainstay at 25 to 29 is not false positives alone; it also includes the transience of infection at that age, and the switch-point analysis of harms against benefits.

---

#Who should be screened, and with what: five bands by age

The recommendations page divides by age into five bands, while the Department has published a service-level method for only two of them, 25 to 29 and 30 to 64. The table separates the two, and "—" means the Department has published no service-level practice for that band.

Look particularly at the 21 to 24 row. This is the second instance of the recommendations page being out of step with the document beneath it: the Group's revised recommendation summary of June 2021 gives that age band a method (cytology), an interval (every three years after two consecutive normal annual screenings) and a modality ("may be screened"); the recommendations page gives none of the three, only "should receive screening based on the doctor's assessment and recommendations" [Note 7].

Whether and how to screen in this band is a question for a doctor.

---

#The two conditions for stopping, of which the Family Health Service page gives only one

The Department's Family Health Service page says: women who have never had sexual experience or have undergone total hysterectomy do not need cervical screening.

But that stopping rule has two conditions, written in two other places in the Government's own material, and the Family Health Service sentence carries neither.

Cervical Screening Programme FAQ question 13: in general, women who have had a hysterectomy with removal of the cervix for benign diseases and without prior history of cervical changes can discontinue screening. The corresponding table in the College's guideline of January 2024 gives the same two conditions [Note 8].

⚠️ Both conditions must hold. If the reason for your hysterectomy was itself a cervical pre-cancerous lesion or cervical cancer, this "you do not need it" rule does not apply to you, and follow-up must be decided by a doctor.

Two more things to check at the same time.

Do you have symptoms? Screening is for people without them. Maternal and Child Health Centres provide cervical screening only, not general gynaecological examination; anyone with abnormal vaginal bleeding or discharge should seek care from a family medicine clinic or a private doctor. Symptoms are not a reason to wait for the next screen; they are a reason to consult.

Do you have risk factors? The Group lists eight: early age at first intercourse, multiple sexual partners, smoking, chronic immunosuppression (people with HIV infection, organ transplant recipients), high parity, young age at first full-term pregnancy, oral contraceptive use for more than five years (returning to never-user levels 10 years or more after stopping), and co-infection with other sexually transmitted infections such as chlamydia.

The Group is equally explicit about what does not count: chemotherapy for non-genital cancers, oestrogen antagonists such as tamoxifen, and long-term biologics show no evidence of increasing CIN risk.

As for 65: the condition for stopping is that routine screenings within the past 10 years were normal. Anyone never screened should still be screened after 65 — the Department states that menopause, years without sex and sterilisation are none of them reasons not to.

---

#How much does screening actually achieve? Three rate ratios and a set of stage figures

The evidence base is a pooled analysis of four European randomised controlled trials, and it carries two figures that are constantly run together.

The study randomised 176,464 women aged 20 to 64 to HPV-based screening or cytology, with a median follow-up of 6.5 years and 107 invasive cervical cancers. The three rate ratios:

In the first 2.5 years the two arms were comparable (0.79). The paper's concluding sentence is that HPV-based screening provides 60–70% greater protection against invasive cervical carcinoma than cytology [Note 9].

That sentence in the original assigns no subgroup, entry condition or time window. The three rate ratios convert to 40%, 55% and 70% respectively; how the 60–70% range was arrived at, the abstract does not say.

The second sentence of the paper's conclusion matters as much: data from large randomised trials support initiation of HPV-based screening from age 30 and extension of screening intervals to at least five years. So what follows about "why 30" and "why five years" is not only the Group's view.

⚠️ When the Group cites the same study, its sentence names the testing modality: it attributes the "40% lower risk of cervical cancer" to co-testing [Note 10]. The two figures cannot be swapped — the 40% converts from the overall rate ratio of 0.60 and the Group attributes it to co-testing, while 60–70% is the paper's unqualified conclusion about HPV-based screening. Different modality, different basis of conversion.

There is a local trial that published both the benefit and the harm, and this article gives both.

The University of Hong Kong randomised 15,955 local Chinese women aged 30 to 60: in the first round the co-testing arm detected CIN2+ in 0.95% against 0.38% in the cytology arm, 2.5 times as many. At the round about 36 months later, CIN2+ in the co-testing arm was lower instead (0.08% against 0.35%, a reduction of about 77%).

That is because the lesions were found a round earlier, not because co-testing found fewer: across both rounds together the co-testing arm's total CIN2+ detection was still higher, 1.01% against 0.66%.

The same paper reports the harm side: 10.6% of the co-testing arm had a colposcopy against 2.4% of the cytology arm, four times as many — so of every 100 women in the co-testing arm referred for colposcopy, about 91 ultimately had no CIN2+. That is the local version of the harm-benefit comparison.

---

#What an interval costs: five figures to read together

The Group cites an International Agency for Research on Cancer study across eight countries. Assuming 100% compliance, the reduction in cumulative incidence among women aged 35 to 64 (screened before 35) by smear interval:

Going from three years to one buys 2.7 percentage points; relaxing from three to five costs 7.2; relaxing to ten costs 26.7. The Group concludes that annual or biennial screening offers only very limited additional protection over three-yearly.

⚠️ Note that this set of figures is entirely about the cytology smear interval, not about HPV testing.

Which is exactly why the official recommendation will not give you "cytology every five years": at five years cytology retains only 83.6%.

Extending HPV testing to five years rests on a different body of research: the cumulative CIN2+/CIN3+ risk over the following two to three rounds among those HPV-negative at entry is lower than among those cytology-negative at entry, which is why extending the HPV-based interval to five years is scientifically sound [Note 11].

The College measures a different comparison: CIN3+ risk within five years of a negative co-test is 0.12%, against 0.33% to 0.52% after a negative cytology alone.

The two sets are not the same thing: the Group's compares HPV-negative against cytology-negative and counts in rounds; the College's compares co-test-negative against cytology-negative and counts in five years. The direction agrees, but the exposed group and the time window both differ, and they cannot be treated as one measurement.

---

#Stage and survival: the strongest argument, and the one to read most carefully

Hong Kong Cancer Registry figures for 2023, with stage distribution and five-year relative survival by stage (patients of 2010–2017):

Which is to say: in 2023 only 18.4% of cases were found at the stage where survival is 90%, and 44.6% had reached stage III or IV.

The Government has a separate figure for the screened population: of cases found through regular cervical screening, over 80% are early stage. "Regular" is a qualifier the original carries; the sentence is not about every case found by screening.

⚠️ The two sets have different denominators — one is all registered cases, the other cases found through regular screening — and the release does not define whether "early" includes stage II, so the two cannot be subtracted.

There is a more fundamental problem of reading. The US National Cancer Institute points out that across 20 major cancers from 1950 to 1996, changes in five-year survival bore little relation to changes in mortality, and that improvements in five-year survival are largely due to earlier diagnosis and to overdiagnosis [Note 12]: lead-time bias means finding something earlier raises survival by itself, even if the time of death does not move.

So the survival figures above are a comparison by stage, and cannot serve as proof of how many lives screening saved. The next sentence of the same passage says what to look at instead: reductions in incidence rates for late-stage tumours are a better measure of screening's effect on mortality than five-year survival trends.

Put another way: the number worth following is whether that 44.6% falls, not whether survival rises.

---

#What screening cannot do: a normal result is not insurance

The Department puts it plainly: if you have symptoms, consult a doctor rather than waiting for the next screen.

The Cervical Screening Programme's symptoms page opens with two sentences: early stage cancer may produce no symptoms at all; the common symptom is abnormal vaginal bleeding. It then lists three bleeding situations and five other symptoms [Note 13]:

The same page states that the presence of any of these does not necessarily mean you have cervical cancer, and that they could be the presenting features of common and benign conditions.

⚠️ But the crucial sentence is this one: you should consult a doctor as soon as possible if you develop any symptoms, even if your latest cervical screening result is normal.

Why is one normal result not insurance? The Department's FAQ question 8 answers directly: cervical cancer can occur in the interval between two screening tests, mainly among women who do not screen regularly; and in some cases the most recent test failed to detect abnormal cells, a false negative [Note 14].

Every screening method has false negatives and false positives — that is not an execution failure but the structure of the method. The World Health Organization explains why the harms are larger than people assume: the great majority of those screened do not have the disease, so more people can be exposed to the harm of screening than may be able to benefit from it [Note 15].

For the cervix specifically, the College notes that women who are HPV-positive with normal cytology should not go straight to colposcopy, because immediate CIN3+ risk is only 2.1%, rising to about 4.8% at five years.

Types differ widely too: ten-year cumulative CIN3+ incidence is 17% for HPV 16, 14% for HPV 18, and only 3% for other high-risk types — the same words "HPV positive" covering close to a sixfold difference between type 16 and the others. About 67% of transient infections clear within 12 months, which is why retesting at 12 months is one option.

Not referring immediately but triaging first is exactly the triage described above.

---

#What the Department opposes is menstrual blood and urine, not self-sampling

Many people think the Department opposes self-sampling. That is backwards.

The press release of 26 October 2025 is headed as a reminder not to use cervical screening methods that lack sufficient scientific evidence. It is aimed at one specific product, and in the same release it endorses another form of self-sampling [Note 16].

Those two ordinances are not general background. They go directly to the mail-the-sample-to-a-laboratory model: the diagnosis must in law be made by a registered doctor, and a registered medical laboratory technologist needs a doctor's referral to carry out a test for diagnostic or treatment purposes.

In other words: vaginal self-sampling is what the Department itself is doing, and menstrual blood sampling is what it is telling you not to use. The College's guideline of January 2024 said the same thing 21 months earlier: self-collected samples such as menstrual blood and urine are not accepted or recommended as standard methods for primary screening. The Centre for Health Protection's release of 2 January 2026 adds that a self-sampling HPV testing scheme would be rolled out at Women Wellness Satellites in the first quarter of 2026.

On the interval, the Department's FAQ question 4 handles the two separately [Note 17]:

• Clinician-collected samples: if the HPV result is normal, screening can be done every 5 years.
• HPV testing of self-collected samples: recommendations and practices vary across the world, from every 3 years to every 5 years, and women should consult their doctor to determine the appropriate interval.

⚠️ So the five-year figure is what the official position states for clinician-collected samples; for self-collected samples the official position is expressly unsettled.

---

#What the three routes cost, and one sum you may get wrong

Three routes publish first-hand prices: Maternal and Child Health Centres, Women Wellness Satellites, and the Family Planning Association.

The nature of the Women Wellness Satellite figures has to be stated first. Its own service charge page says it operates on a co-payment model: eligible people receive partial government subsidy and pay a prescribed co-payment. So those figures are co-payments with a government subsidy behind them, not the full cost of the service.

The structure matters too: cervical cancer screening (cervical cytology) is a "basic service"; HPV DNA testing and HPV self-sampling are "value-added services", charged separately.

"Eligible persons" at a Maternal and Child Health Centre means holders of a Hong Kong Identity Card issued under the Registration of Persons Ordinance and others approved by the Director of Health, with booking through the 24-hour hotline 3166 6631. The Department also states that screening should avoid the menstrual period, that women aged 45 or above should book after day 12 of the cycle, and that vaginal pessaries, sex and douching should be avoided for two days before.

Now the sum: how many screens between 30 and 64, costed at each of the three.

The counts first:

• Cytology route (every three years): after two consecutive normal annual screenings, so 30, 31, then 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64 — 13 in all.
• Five-yearly route (HPV testing or co-testing): 30, 35, 40, 45, 50, 55, 60 — 7 in all (65 is outside this age band).
• Difference in count: (13 − 7) ÷ 13 = 46.2%, so 46% fewer.

Now multiply by price:

The result is counter-intuitive: 46% fewer visits, and at the Family Planning Association the total is $1,540 more. At a Women Wellness Satellite the HPV DNA route is $1,550 more than cytology and the self-sampling route $200 less; at a Maternal and Child Health Centre the difference is $600, spread across 35 years.

⚠️ The self-sampling sum needs a discount on the claim. The Department states that the five-year interval is for clinician-collected samples, and that for self-collected samples appropriate intervals vary from three to five years and are unsettled. The 7 above is the five-year end; at three-yearly (30, 33 … 63, so 12) it becomes 12 × $250 = $3,000, which is more than 13 cytology screens. So the "cheaper" conclusion holds only at a five-year interval.

In one sentence: fewer visits does not mean cheaper — which route is cheaper depends mostly on where you go and which test you have.

And "fewer visits and cheaper" is not only the self-sampling combination: a Maternal and Child Health Centre is one too. 7 × $100 = $700 against 13 × $100 = $1,300 saves $600, and that sum is the sounder one — the Centre does not price by test method, so the 7 depends only on routine clinician-collected HPV testing every five years, rather than resting on an interval the official position calls unsettled.

The Family Planning Association publishes no price for HPV testing alone, so that cell can only compare cytology against co-testing.

⚠️ All three columns cover the test item only, and exclude consultation and nursing charges. At a Women Wellness Satellite those are "doctor assessment and consultation" at $150 and "dedicated nurse clinic" at $80; at the Family Planning Association a consultation fee of $220 and a nursing fee of $80. The two providers' item names and amounts differ and cannot be merged. And the Women Wellness Satellite column is a co-payment with government subsidy behind it while the Family Planning Association column is the full fee, so the two are different in kind and cannot be compared as though they were the same price.

Other routes: the providers the Department lists include Maternal and Child Health Centres, Women Wellness Satellites under the Primary Healthcare Commission, family doctors, gynaecologists and non-governmental organisations; that list states of itself that it covers only organisations registered with the Cervical Screening Information System, and is not exhaustive. Users of a Women Wellness Satellite must first register as a District Health Centre member and consent to join the electronic health record.

---

#Three substantive differences between the College and the Government

The College's guideline as revised in January 2024 differs from the Government's position in at least five places; the three most substantive are [Note 18]:

The other two differences: the College has a row reading "Under 25 — Screen as per physician's assessment of risk", with no lower bound; and hysterectomy is an explicit row in the College's table, while on the Government side it is split between the Family Health Service page and FAQ question 13, and the recommendations page itself does not carry it.

⚠️ The first is the most substantive, but the timing has to be stated. The Childhood Immunisation Programme has vaccinated Primary Five schoolgirls since the 2019/20 school year, and the first cohort (born around 2008) will not turn 25 until about 2033; those born 2004 to 2008 and covered by the catch-up programme reach 25 between 2029 and 2033. So the College's provision does not yet apply to the great majority of women now aged 25 to 29.

Another instance of official pages being out of step sits on the same page: the "More Information" link on the Programme's recommendations page still points to the College's guideline of November 2016, while the College published its revision in January 2024. The Chinese version of the same page also notes that the Expert Working Group's recommendations and the College's guideline are available in English only — so a Chinese reader has no Chinese version of the underlying documents to read.

---

#Do the official figures conflict? A thirty-year decline and a recent rise can both be true

The two official documents describe different time windows; they do not contradict each other.

The Group's document of June 2021 (based on 2018 incidence and 2019 mortality) states that both age-standardised incidence and mortality showed a downward trend over the past three decades. The Centre for Health Protection on 20 January 2026 states that the age-standardised incidence rate has shown a slight upward trend in recent years, with age-standardised mortality broadly stable over the same period [Note 19].

The Cancer Registry's 2023 figures, published August 2025, quantify both: the average annual percentage change in the age-standardised incidence rate over the past ten years is +0.9%, with an asterisk marking statistical significance at the 0.05 level; mortality over the same period is −0.4%, with no asterisk.

So "there is a screening programme" should not be read as "the problem is shrinking".

The 2023 baseline: 576 new cases, 3.0% of female cancers, ranked 7th; 173 deaths, ranked 9th; median age at diagnosis 55.5. Those are the most recent complete incidence figures available; mortality is one year further forward — the Centre for Health Protection's cervical cancer page and the Department's release of 28 May 2026 both give 160 deaths in 2024. (The Department's October 2025 release cites 2022 figures instead: ninth most common, 522 new cases, 167 deaths, which is not the current year.)

The age distribution deserves more attention. Among women aged 20 to 49, cervical cancer ranks fourth: 193 cases, 5.8% of that age group's 3,313 female cancers, behind breast, thyroid and corpus uteri. In the top-five lists for 50–64, 65–74 and 75 or above it does not appear at all.

By five-year band the rise is clearly placed (per 100,000 female population, 2023):

From 25–29 to 35–39 the incidence rises nearly sevenfold. For women in that band the risk is not something for later; it is climbing during those ten years.

---

#Vaccination does not replace screening; what Hong Kong lacks in the WHO's three pillars is screening

The vaccine prevents and screening detects; neither substitutes for the other.

The Department's FAQ states that regular screening is still needed after HPV vaccination, because the vaccine does not cover all types and cannot clear an existing infection. The College's wording is that current vaccines cannot provide complete protection.

On vaccination Hong Kong does very well. The Controller of the Centre for Health Protection said in the release of 28 May 2026 that the two-dose HPV vaccination completion rate among 15-year-old girls in Hong Kong has exceeded 90%, far above the 70% interim target coverage set for schoolgirls in the Hong Kong Cancer Strategy, and has achieved ahead of time the WHO global strategy target of 90% of girls fully vaccinated by the age of 15 before 2030 [Note 20].

⚠️ But one thing here is highly time-sensitive, and you have to judge it for yourself. The same release states that the one-off HPV vaccination catch-up programme — for female Hong Kong residents born 2004 to 2008 who were not covered by the Childhood Immunisation Programme — recommends the first dose on or before 30 June 2026, so that the series can be completed before the programme ends on 31 December 2026; those who miss it must arrange vaccination themselves and bear the full cost. As at May 2026 first-dose coverage in that group was estimated at over 60%.

This article was verified on 9 August 2026 — the recommended first-dose date has passed.

What would self-paid vaccination cost later? The Centre for Health Protection said on 20 January 2026 that a dose may exceed $1,200, and two first-hand published prices exist: the Family Planning Association's nine-valent HPV vaccine at $1,700 a dose, and the Women Wellness Satellite's "HPV vaccine (outside the Government catch-up programme)" at $1,500 a dose. (On the Satellite's page $1,500 is set expressly against the "HPV vaccine" row; the $2,500 immediately below it is the shingles vaccine, not HPV.)

The three figures are on different bases — one is a government estimate of the future self-paid level and two are published institutional prices, and the Satellite's is a co-payment, so they cannot be compared directly.

As for the WHO framework. The strategy to eliminate cervical cancer, adopted by the World Health Assembly in August 2020, rests on three pillars, 90–70–90: 90% of girls fully vaccinated against HPV by age 15; 70% of women screened with a high-performance test by 35 and again by 45; and 90% of women with pre-cancer treated and 90% with invasive cancer managed. The elimination threshold is an incidence rate below 4 per 100,000 women [Note 21].

Hong Kong's position:

⚠️ The two rulers in the screening row are not the same: Hong Kong measures "ever had one", while the WHO asks for a high-performance test once before 35 and again before 45. Hong Kong's ruler is the looser one, so the real gap may be larger than the 20 percentage points on the surface.

The incidence row needs one thing said first: Hong Kong publishes no figure that can be compared strictly like-for-like with the WHO threshold.

The WHO's English page and the body of its official Chinese version both set the threshold only as an incidence below 4 per 100,000 women (the Chinese version stating that this is annual), with the basis of judgement placed on incidence data from population-based cancer registries; neither version states which standard population is used, and the English page does not even say whether the threshold is an age-standardised rate.

On the Hong Kong side, the same year and the same registered cases (576 in 2023) yield three published incidence figures:

8.3 and 7.6 are not two contradictory things; they are the same cases computed against two different standard populations. The Registry's footnote states expressly that comparison with rates from other sources is meaningful only on the same standard population — and the WHO does not publish which one it uses, so that condition fails equally for 8.3 and for 7.6.

The only sound comparison is this: all three figures exceed 4 — the smallest, 7.6, is close to twice the threshold, and the crude rate of 14.0 more than three times it. Whichever standard population is used, Hong Kong is some distance from the elimination threshold, and the last ten years have moved upward.

---

#Why has Australia moved faster? The word "invited"

Australia's national programme moved to HPV testing as the primary screen on 1 December 2017, and on 1 July 2022 extended self-sampling eligibility to everyone eligible aged 25 to 74.

The figures that follow must be read with their denominator. One study defines "self-sampling uptake" as the proportion of all valid HPV tests each quarter that were self-collected — the denominator is tests performed, not people, and not the eligible population.

On that definition the proportion rose from 1.2% in the second quarter of 2022 to 26.9% in the fourth quarter of 2023; among tests done by people more than 10 years overdue for screening it was 51.9%, in very remote areas 53.9%, in socioeconomically disadvantaged areas ≤29.1%, and in the 70 to 74 group 33.5% [Note 22].

⚠️ That set proves that when these people do get tested they choose self-sampling in large proportions — not directly that their screening rate rose by any number of percentage points. The latter needs one further inference, which the paper does not supply. The authors' conclusion is that universal self-sampling substantially increased cervical screening uptake in under-screened populations.

A modelling study funded by the Australian health department before the change predicted that five-yearly primary HPV testing would reduce incidence and mortality by 31% and 36% in unvaccinated cohorts and 24% and 29% in cohorts offered vaccination [Note 23].

But the comparator arm is itself the argument: it compared against the programme of the time — cytology every two years for women aged 18 to 69. That is a long way from Hong Kong's current practice, so those percentages cannot be read as what Hong Kong would save by changing.

The largest structural difference is really the word "invited". The Australian health department's programme page reads: women and people with a cervix aged 25 to 74 are invited to have a Cervical Screening Test every five years [Note 24].

The WHO, describing ad hoc screening arrangements, writes that they rely on individuals to take up the offer or refer themselves. An organised programme, by contrast, calls and recalls from a register of the eligible population, which raises participation and narrows socioeconomic gaps.

On the Hong Kong side, the Group's 2021 document states that further local research is recommended because local cost-effectiveness data are lacking; and Australia has had a national vaccination programme since 2007 against Hong Kong's 2019/20 school year, so most women now aged 25 to 29 in Hong Kong are unvaccinated.

---

#What to do next

1. Place yourself in a band first. 25 to 29 is cytology; for 30 to 64 the Department's service default is HPV testing.
2. Do not use the recommendations page's three options to judge which one the service will give you. Those three are the 2021 recommendation as written.
3. Before comparing prices, look at where you will go. A Maternal and Child Health Centre charges per visit and does not price by method, at $100 a visit; fewer visits does not mean a lower total.
4. If you have symptoms, consult a doctor rather than waiting for the next screen. Abnormal vaginal bleeding and foul-smelling discharge are the two commonest, and the Department states that you should consult promptly even if your latest result was normal.
5. If you have had a hysterectomy, check both conditions. For benign disease, and without prior history of cervical changes — both must hold before screening stops.
6. Vaccination does not remove the need to screen. The vaccine does not cover all types and cannot clear an existing infection.
7. If you were born 2004 to 2008 and are unvaccinated, the catch-up programme's recommended first-dose date has passed and the programme ends on 31 December 2026. Ask the programme directly about what is still possible.

---

#Frequently asked questions

Can I choose freely among the three official methods?

The recommendations page does list three methods for ages 30 to 64, but the Department's FAQ page and its press release of 26 October 2025 both state that since April 2023 the Department has adopted HPV testing as the primary screening method for women aged 30 to 64. Ages 25 to 29 remain on cytology.

Why is HPV testing not used for ages 25 to 29?

The official reason is that HPV infection in this age group is largely transient, so testing may lead to unnecessary follow-up tests and medical procedures, and colposcopy referral rates are higher (2.3% to 13.1% for HPV-based testing under 30, against 1.9% to 4.7% for cytology). One thing has to be added: the same document also states that where an HPV-positive result is triaged by cytology, the false-positive rate and the colposcopy referral rate become comparable with cytology, so "more false positives" describes the untriaged approach. The College of Obstetricians and Gynaecologists' 2024 guideline does allow an HPV-based test to be considered in women who have had HPV vaccination.

My last screen was normal — can I ignore it?

No. The Department's FAQ question 8 states that cervical cancer can occur in the interval between two screening tests, and the symptoms page states that you should consult a doctor as soon as possible if you develop any symptoms, even if your latest result was normal. The commonest are abnormal vaginal bleeding (between periods, during or after sex, after menopause) and foul-smelling vaginal discharge.

Is the Department telling people not to use self-sampling?

No. The press release of 26 October 2025 is aimed at menstrual blood and urine samples; the same release cites the WHO that vaginal self-sampling for HPV testing is another reliable method for cervical screening, and states that since June 2024 the Department has run a pilot scheme on HPV testing of self-collected samples at 11 Maternal and Child Health Centres.

Is self-sampling also every five years?

The official position does not say so. FAQ question 4 separates the two: for clinician-collected samples, screening can be done every 5 years if the HPV result is normal; for self-collected samples, recommendations and practices vary across the world from every 3 years to every 5 years and are unsettled, and women should consult their doctor about the appropriate interval.

When can I stop?

The recommendations page: women aged 65 or above may discontinue if routine screenings within 10 years are normal, and those never screened should still be screened. The College's 2024 guideline additionally requires never having been diagnosed histologically with high-grade squamous intraepithelial lesion. On hysterectomy, the official conditions are removal of the cervix for benign diseases and without prior history of cervical changes — both must hold. Whether stopping is actually appropriate is for a doctor to assess.

Which route is cheapest?

It depends where you go. Across ages 30 to 64: Family Planning Association 13 cytology screens $4,550 against 7 co-tests $6,090; Women Wellness Satellite co-payments 13 cytology $1,950 against 7 HPV DNA $3,500 or 7 self-sampling $1,750; Maternal and Child Health Centre at $100 a visit, 13 for $1,300 against 7 for $700. Having 46% fewer visits does not automatically make it cheaper.

Do I still need screening if I have had the HPV vaccine?

Yes. The vaccine does not cover all types and cannot clear an existing infection; the College's wording is that current vaccines cannot provide complete protection.

How far is Hong Kong from the WHO elimination target?

The vaccination pillar is met. The screening pillar is about 20 percentage points short, and Hong Kong measures "ever had one" against the WHO's requirement of one high-performance test before 35 and another before 45, so the real gap may be larger. On incidence, the three figures published for 2023 — crude 14.0, age-standardised 8.3 (WHO 2000) and age-standardised 7.6 (Segi 1960) — all exceed the threshold of 4 per 100,000 a year; the WHO does not publish which standard population its threshold uses, so none of the three is a strictly like-for-like comparison.

---

#What this article does not state

For each item below there was no verified first-hand source to cite, so this article does not state it and does not fill the gap with inference. Each names the source consulted and the date.

• The government subsidy behind the Women Wellness Satellite co-payments. Its service charge page (retrieved 9 August 2026, all 22 charge lines read) publishes participant co-payments only and not the government's share, so this article does not state the full cost of the service.
• How the Satellite's "basic" and "value-added" services combine. The same page prices each item separately and does not say whether HPV DNA testing or self-sampling is charged together with the basic cervical screening, so this article lists items separately and does not add them.
• The Family Planning Association's price for HPV testing alone. Reading its whole fee table line by line, the cervical screening entries are only $350 for cytology and $870 for co-testing, so that cell can only compare cytology against co-testing.
• Effect estimates from the Compass trial (Australia, conducted in a vaccinated population). Neither the professional document of June 2021 nor the 2026 paper cited here carries them, and this article has not cited the trial's own literature. This item holds only in respect of those two documents; the trial's primary literature is publicly available, and this is not a claim that it cannot be obtained, only that unverified literature will not be used to supply figures.
• The NTCC trial's own primary literature. It is named in the methods of the 2014 pooled analysis, but the June 2021 professional document's reference list has no separate entry for it.
• Live pages on the Australian government website. health.gov.au was still not responding on 9 August 2026 (ncsr.gov.au and aihw.gov.au were used as controls and both returned real HTTP status codes, so this was not a local network problem), so this article does not cite its current pages: the Australian programme's dates and parameters come instead from a journal paper co-authored by staff of the Cervical Screening Section of the Australian health department, and the programme description from an archived capture of that department's page dated 14 May 2026, marked as an archived copy rather than a live page both in the text and in the sources.
• The territory-wide annual number of cervical screens, including the private sector and non-governmental organisations. The Government publishes one component: the indicator table in the Controlling Officer's Report for Head 037 (Department of Health) of the 2026-27 Estimates gives cervical screening attendances of 63 000 in 2024, 64 000 in 2025 and a 2026 estimate of 64 000. That covers Maternal and Child Health Centres only and excludes private doctors, gynaecologists and non-governmental organisations, which account for a substantial share; no territory-wide total is published. The Cervical Screening Programme website has no statistics page of its own.
• A local overdiagnosis proportion. Neither the June 2021 document, the College's 2024 guideline, the Centre for Health Protection nor the Programme website carries a local overdiagnosis or overtesting proportion. On the false-positive side local data do exist: see the colposcopy proportions from the University of Hong Kong trial above.
• The standard population behind the WHO elimination threshold. Neither the WHO's English page nor the whole of its official Chinese version states it, so this article does not designate any Hong Kong incidence figure as comparable with that threshold.
• This article assesses no doctor, clinic, organisation or product, and offers no medical advice for any individual; which method to use, and when to start and stop, must be decided by a doctor on individual circumstances.

---

#Notes: the official wording

Where a source publishes in English, the wording below is the source's own. Where a source has no English edition, the rendering is ours and is marked as such, with the original set out alongside so it can be checked.

[Note 1] Department of Health press release, 26 October 2025:

In response to the recommendation of the Cancer Expert Working Group on Cancer Prevention and Screening (CEWG), the DH adopted HPV testing using cervical cells as the primary approach of cervical screening for women aged 30 to 64 since April 2023.

The Programme's FAQ page is fuller:

In light of HPV testing's higher sensitivity for earlier detection of precancerous lesions and longer screening interval, starting from April 2023, the Department of Health (DH) has transitioned to HPV testing as the primary screening method for cervical cancer for women aged 30 to 64.

[Note 2] The Cancer Expert Working Group states that it deliberated against the WHO's ten screening principles of Wilson and Jungner, 1968, one of which is:

The natural history of the condition, including development from latent to declared disease, should be adequately understood.

A note on the source: the body of that overview document writes "Wilson & Jungner", while the heading of the third table in its Appendix I misspells the surname as "Wilson and Junger's"; this article follows the body.

[Note 3] Where the three pairs come from: the recommendations page — "Cervical screening is for healthy women who do not have symptoms."; the press release of 26 October 2025 — that a screening result is a reference only and cannot replace a doctor's professional diagnosis; and the 90%-clearance sentence from the Expert Working Group's document of June 2021, whose original condition is "in women with normal immune systems".

[Note 4] The US National Cancer Institute on positive predictive value and prevalence:

For a given sensitivity and specificity, the lower the prevalence, the lower the PPV and the higher the NPV

[Note 5] The Government's reason for not using HPV testing at 25 to 29, from the English edition of the same release:

in view of their higher prevalence of transient HPV infection, HPV testing may lead to unnecessary follow-up test and medical procedures

[Note 6] Paragraph 15 of the Expert Working Group's document of June 2021, on triage:

Triage is necessary to limit the higher false-positive rate and colposcopy rate associated with HPV-based testing

The same paragraph recommends cytology or HPV 16/18 genotyping as a second-line triage test before deciding who needs colposcopy.

[Note 7] The 21 to 24 band, from the Expert Working Group's revised recommendation summary of June 2021:

may be screened by cytology every three years after two consecutive normal annual screenings, depending on doctor's assessment

The recommendations page says only that they "should receive screening based on the doctor's assessment and recommendations", giving neither the method, the interval nor the "may".

[Note 8] The stopping rule in three places. The Family Health Service page:

Women who have never had sexual experience or have undergone total hysterectomy do not need cervical screening.

Cervical Screening Programme FAQ question 13:

In general, women who have hysterectomy with removal of cervix for benign diseases and without prior history of cervical changes can discontinue screening. If in doubt, please consult your doctor.

The corresponding table in the College's guideline of January 2024 gives the same two conditions: "for benign diseases" and "without a prior history of cervical dysplasia".

[Note 9] The concluding sentences of the pooled analysis of four European randomised controlled trials:

HPV-based screening provides 60-70% greater protection against invasive cervical carcinomas compared with cytology

Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years.

[Note 10] The modality the Expert Working Group names when citing the same study:

A pooled analysis of four European randomised controlled trials (RCTs) indicated HPV-based screening as co-testing (i.e. both HPV testing and cytology) was associated with 40% lower risk of cervical cancer when compared with cytology.

[Note 11] The scientific basis for the five-year interval, in the Expert Working Group's words:

extension of screening interval to 5 years for HPV-based screening is scientifically sound

Its definition: the cumulative CIN2+/CIN3+ risk over the following two to three rounds among those HPV-negative at entry is lower than among those cytology-negative at entry.

[Note 12] Two sentences from the US National Cancer Institute on five-year survival:

Thus, improvements in 5-year survival rates are largely due to earlier diagnosis and to overdiagnosis

Reductions in incidence rates for late-stage tumors represent a better measure of decreased cancer mortality due to screening than do 5-year survival trends.

The data basis for that passage is SEER data on 20 major cancers from 1950 to 1996.

[Note 13] The Cervical Screening Programme's symptoms page, its opening sentences and its most important one:

Early stage of cancer may produce no symptoms at all.

The common symptom is abnormal vaginal bleeding, which could occur:

You should consult a doctor as soon as possible if you develop any symptoms, even if your latest cervical screening result is normal.

The same page also states that the presence of any of these symptoms does not necessarily mean you have cervical cancer, and that they could be the presenting features of some common and benign conditions.

[Note 14] Cervical Screening Programme FAQ question 8, on cancer arising between screens: cervical cancer can occur in the interval between two screening tests, mainly among women who do not have regular cervical screening; and some cases arise because the most recent test failed to detect abnormal cells, a false negative. The same page states that all screening methods have their limitations and none is completely accurate.

The Department's press release of October 2025 points the same way: any screening method has limitations, including false negative and false positive results.

[Note 15] World Health Organization, Screening programmes: a short guide (2020):

more people can be exposed to the harm of screening than may be able to benefit from it

[Note 16] The Department's press release of 26 October 2025. What it targets:

there is currently insufficient scientific evidence, both locally and internationally, to confirm the reliability of using menstrual blood for cervical screening

What it endorses:

In addition to healthcare professionals collecting cervical samples for cytology or HPV testing, the World Health Organization recommended that vaginal self-sampling for HPV testing as another reliable method for cervical screening. Hence, from June 2024, the DH launched a Pilot Scheme on HPV Testing of Self-collected Samples at 11 Maternal and Child Health Centres

The two ordinances it cites: under the Medical Registration Ordinance (Cap. 161) any medical diagnosis must be performed by a registered medical practitioner; and under the Supplementary Medical Professions Ordinance (Cap. 359) and its subsidiary legislation, a registered medical laboratory technologist may not carry out any test or examination for the purpose of medical diagnosis or treatment except upon the referral of a registered medical practitioner.

This article checked that release sentence by sentence: it names no company and no product, publishes no price, alleges that no operator has breached those ordinances, and changes no screening recommendation.

[Note 17] Cervical Screening Programme FAQ question 4, handling the two sampling methods separately: for clinician-collected samples, "screening can be done every 5 years if the results are normal"; for self-collected samples, "currently the recommendations and practices of screening interval vary across the world, from every 3 years to every 5 years"

[Note 18] Three passages from the College's Guidelines for Cervical Cancer Prevention and Screening, Guideline No. 4 (revised January 2024). On 25 to 29: "HPV-based test (HPV stand-alone or HPV co-test with cytology) can be considered in women who had HPV vaccination". On stopping at 65: "and they were not previously diagnosed to have high-grade squamous intraepithelial lesion (HSIL) histologically", with a "last 25 years" rule for those who were. On chronic immunosuppression: "Chronically immunosuppressed should be screened regardless of age when they have become sexually active". The Government's recommendations page places chronic immunosuppression under "other women at higher risk", who it says should be assessed by a doctor and may need more frequent screening.

[Note 19] The two time windows. The Expert Working Group's document of June 2021 (based on 2018 incidence and 2019 mortality):

Both ASIR and ASMR of cervical cancer showed a downward trend over the past three decades.

The Centre for Health Protection, 20 January 2026:

the age-standardised incidence rate of cervical cancer has shown a slight upward trend in recent years

[Note 20] The Department's press release of 28 May 2026, quoting the Controller of the Centre for Health Protection:

Hong Kong has exceeded the high level of 90 per cent for the two-dose HPV vaccination completion rate among girls aged 15, which not only far surpasses the interim target coverage of 70 per cent for HPV vaccination among schoolgirls set out in the Hong Kong Cancer Strategy, but also achieves ahead of schedule the WHO's global strategy target for cervical cancer elimination of 90 per cent of girls fully vaccinated with HPV vaccine by age of 15 years before 2030

The same release states that the catch-up programme recommends the first dose on or before 30 June 2026 and that the programme ends on 31 December 2026.

[Note 21] The WHO elimination threshold, from its English page:

all countries must reach and maintain an incidence rate of below 4 per 100 000 women

That English page states neither the time unit nor the standard population. The body of the WHO's official Chinese version of Global strategy to accelerate the elimination of cervical cancer as a public health problem does state that it is an annual rate. That sentence has no English counterpart carrying the qualifier. This article therefore reports its content rather than quoting it: the Chinese version puts the minimum target for eliminating cervical cancer as a public health problem at fewer than 4 cases per 100,000 women per year. The original sentence, in the simplified characters the WHO prints:

作为一个公共卫生问题消除宫颈癌的最低目标是每年每10万名妇女的发病人数在4人以下

The WHO publishes no traditional-Chinese or Hong Kong version of that target; apart from the sentence above, this article does not reproduce the WHO's other Chinese wording and paraphrases instead.

[Note 22] Australian self-sampling uptake is defined as the proportion of all valid HPV tests each quarter that were self-collected — the denominator is tests, not people, and not the eligible population. The authors' conclusion:

substantially increased cervical screening uptake in under-screened populations

The "≤29.1%" for socioeconomically disadvantaged areas is the original's own notation.

[Note 23] The comparator arm of the pre-transition Australian modelling study — cytology every two years for women aged 18 to 69 — is written in the original as "cytological screening every 2 years for women aged 18-69 years"; the benefiting cohort is described in the original as "cohorts offered vaccination", which is an intention-to-treat grouping including those who were never vaccinated, and is not the same as "vaccinated cohorts". The full strategy was direct colposcopy referral for HPV 16/18 positives, with reflex cytology triage for other oncogenic types. A further note: the paper's conclusion says the transition "will occur in May, 2017", while the actual transition date was 1 December 2017; this article follows the date given in the 2026 paper.

[Note 24] The Australian programme description, quoted from an archived capture of the department's page dated 14 May 2026 rather than a live page:

Women and people with a cervix aged 25 to 74 years of age are invited to have a Cervical Screening Test every 5 years.

The WHO, describing ad hoc arrangements, writes "rely on individuals to take up the offer or refer themselves" — that cell describes an arrangement where "Offers of screening are ad hoc", and is not the name of a category called "unorganised model".

---

#Sources and dates checked

• Screening target, age bands, intervals, the provisions for 21–24 and 65 or above, the "other women at higher risk" sentence, the note that the CEWG and College guidelines are available in English only, and the recommendations page's link pointing to the College's 2016 guideline: Cervical Screening Programme, "Screening Target and Recommendations", Department of Health: https://www.cervicalscreening.gov.hk/tc/recommendations.html (retrieved 9 August 2026); the "screening by cytology every 3 years" sentence for ages 25–29: the English version of the same page https://www.cervicalscreening.gov.hk/en/recommendations.html (retrieved 9 August 2026)
• The symptom list, the three bleeding situations, foul-smelling discharge, and "You should consult a doctor as soon as possible if you develop any symptoms, even if your latest cervical screening result is normal.": Cervical Screening Programme, "Symptoms", Department of Health: https://www.cervicalscreening.gov.hk/tc/symptoms.html (retrieved 9 August 2026)
• HPV testing as the primary method for ages 30–64 since April 2023, the three methods listed side by side for 30–64, screening still being needed after vaccination, and the categories of service provider: Cervical Screening Programme FAQ, English version, Department of Health: https://www.cervicalscreening.gov.hk/en/faq.html (retrieved 9 August 2026)
• Question 3 on menopause, years without sex and sterilisation; question 4 on the five-year interval for clinician-collected samples and the unsettled interval for self-collected; question 8 on cancer between screens and false negatives; question 13 on the two conditions for hysterectomy: the Chinese version of the same FAQ: https://www.cervicalscreening.gov.hk/tc/faq.html (retrieved 9 August 2026)
• The provider list covering only organisations registered with the Cervical Screening Information System: the same programme's "Where to Get Screened": https://www.cervicalscreening.gov.hk/en/serviceproviders.html (retrieved 9 August 2026)
• The scope of the October 2025 reminder, menstrual blood and urine samples, the vaginal self-sampling pilot, ages 25–29 continuing on cytology, the two passages on the Medical Registration Ordinance (Cap. 161) and the Supplementary Medical Professions Ordinance (Cap. 359), the limitations of screening, and the 2022 case figures: "DH reminds public not to use cervical screening methods that lack sufficient scientific evidence", Government press release, 26 October 2025: https://www.info.gov.hk/gia/general/202510/26/P2025102500832.htm (retrieved 9 August 2026; the wording quoted here is that of the English edition of the same release)
• 576 new cases in 2023, a slight recent rise in incidence, broadly stable mortality, about 50% of eligible women ever screened, and self-paid vaccine possibly over $1,200 a dose: Government press release, 20 January 2026: https://www.info.gov.hk/gia/general/202601/20/P2026012000780.htm (retrieved 9 August 2026)
• 2023 crude incidence 14.0 and age-standardised incidence 8.3 (WHO 2000 standard population, GPE Discussion Paper No.31), 160 deaths in 2024 and age-standardised mortality 1.8: Centre for Health Protection health topic "Cervical Cancer" (page states revised 23 January 2026): https://www.chp.gov.hk/en/healthtopics/content/25/56.html (retrieved 9 August 2026)
• Self-sampling to be rolled out at Women Wellness Satellites in the first quarter of 2026: Government press release, 2 January 2026: https://www.info.gov.hk/gia/general/202601/02/P2026010200257.htm (retrieved 9 August 2026)
• The catch-up programme's recommended first-dose date, its end date, the self-paid arrangement afterwards, first-dose coverage over 60%, the two-dose completion rate among 15-year-old girls exceeding 90%, the 70% interim target in the Hong Kong Cancer Strategy, the WHO vaccination target, and 160 deaths in 2024: Government press release, 28 May 2026: https://www.info.gov.hk/gia/general/202605/28/P2026052800271.htm (retrieved 9 August 2026); the English edition of the same release: https://www.info.gov.hk/gia/general/202605/28/P2026052800447.htm
• The catch-up programme's target group (born 2004 to 2008), the two-dose arrangement, and the school year the Childhood Immunisation Programme began: Government press release, 6 November 2024: https://www.info.gov.hk/gia/general/202411/06/P2024110600414.htm (retrieved 9 August 2026)
• Over 80% of cases found through regular screening being early stage (the original carries the qualifier "regular"): Government press release for World Cancer Day, 4 February 2026: https://www.info.gov.hk/gia/general/202602/04/P2026020400274.htm (retrieved 9 August 2026)
• The co-payment model of the Women Wellness Satellites and the requirement to register as a District Health Centre member first: Government press release, 23 January 2025: https://www.info.gov.hk/gia/general/202501/23/P2025012300552.htm (retrieved 9 August 2026); the services offered (HPV DNA testing, HPV self-sampling): Government press release, 7 July 2026: https://www.info.gov.hk/gia/general/202607/07/P2026070700266.htm (retrieved 9 August 2026)
• Women Wellness Satellite co-payments (cervical cancer screening by cytology $150, HPV DNA testing $500, HPV self-sampling $250, doctor assessment and consultation $150, dedicated nurse clinic $80, HPV vaccine outside the Government catch-up programme $1,500 a dose), the wording of the co-payment model, and the split between basic and value-added services: Women Wellness Satellite, "Service Charges": https://www.wws.org.hk/page/service-charge (page states last updated 6 July 2026; retrieved 9 August 2026). That site publishes in Chinese only; its English path returns a page-not-found, so this article reports its content rather than quoting it.
• About 90% of HPV infections clearing within two years (with the condition "in women with normal immune systems"), the scientific basis for the five-year interval and its definition, the five interval percentages from the IARC eight-country study (93.5% yearly, 92.5% two-yearly, 90.8% three-yearly, 83.6% five-yearly, 64.1% ten-yearly), the "40% lower risk" sentence attributed to co-testing, the harm-benefit switch at 30 and "using colposcopy as a proxy for harms", colposcopy referral rates, cytology triage bringing false-positive and colposcopy rates to parity with cytology, "Triage is necessary…", the local University of Hong Kong randomised trial (including the higher two-round total detection), the method and interval for 21–24 (from the revised recommendation summary), the eight risk factors and the negative findings, the absence of local cost-effectiveness data, and the thirty-year downward trend: Cancer Expert Working Group on Cancer Prevention and Screening, Recommendations on Prevention and Screening for Cervical Cancer — For Health Professionals (June 2021), Centre for Health Protection: https://www.chp.gov.hk/files/pdf/cervical_cancer_professional_hp.pdf (retrieved 9 August 2026)
• The CEWG's adoption of the Wilson and Jungner principles (as written in the body; the heading of the third table in Appendix I misspells the surname as "Wilson and Junger's"), and the years the Coordinating Committee and the CEWG were established: Recommendations of CEWG – An Overview for Health Professionals (June 2018), Centre for Health Protection: https://www.chp.gov.hk/files/pdf/overview_of_cewg_recommendations_professional_hp.pdf (retrieved 9 August 2026)
• Rate ratios 0.60, 0.45 and 0.30, and the 60–70% conclusion together with its second sentence (initiation from age 30 and extension of intervals to at least five years): Ronco G, Dillner J, Elfström KM, et al. Lancet 2014;383(9916):524-32 (DOI 10.1016/S0140-6736(13)62218-7; PMID 24192252)
• The University of Hong Kong trial's CIN2+ detection of 0.95%/0.38%, 0.08%/0.35% at the second round, 1.01%/0.66% across both, and colposcopy proportions of 10.6%/2.4%: Chan KKL, Liu SS, Wei N, et al. Int J Cancer 2020;147(4):1152-1162 (DOI 10.1002/ijc.32861; PMID 31922265)
• HPV-based testing being considerable for vaccinated women aged 25–29, screening under 25 on physician assessment, the HSIL condition and 25-year rule for stopping at 65, the hysterectomy row (with "for benign diseases" and "without a prior history of cervical dysplasia"), chronic immunosuppression, CIN3+ risk of 0.12% against 0.33–0.52%, 2.1% and 4.8%, 17%/14%/3% by type, 67% clearing within 12 months, the harms of transient infection, menstrual blood and urine not being standard methods, and vaccines not providing complete protection: Hong Kong College of Obstetricians and Gynaecologists, Guidelines for Cervical Cancer Prevention and Screening, Guideline No. 4 (revised January 2024): https://www.hkcog.org.hk/hkcog/Download/Guidelines_for_Cervical_Cancer_Prevention_and_Screening.pdf (retrieved 9 August 2026); journal version: Ngu SF, et al. Hong Kong Med J 2024;30(6):488-497 (DOI 10.12809/hkmj2411547; PMID 39623938)
• 576 new cases and 173 deaths in 2023, the rankings, median age, crude rate 14.0, age-standardised rate 7.6 (Segi 1960), ten-year average annual percentage change of +0.9%/−0.4%, stage distribution, five-year relative survival by stage, and the Segi 1960 footnote: Hong Kong Cancer Registry, Cervical Cancer in 2023 (August 2025): https://www3.ha.org.hk/cancereg/pdf/factsheet/2023/cx_2023.pdf (retrieved 9 August 2026)
• Cervical cancer incidence by five-year age group in 2023 (per 100,000 female population): Hong Kong Cancer Registry, Cancer Statistics Query System (All Ages): https://www3.ha.org.hk/cancereg/allages.asp (query: incidence, female, five-year groups, 2023, cervix; retrieved 9 August 2026. The case numbers and all-age crude and standardised rates returned by that query agree exactly with the statistics document above)
• Cervical screening attendances at Maternal and Child Health Centres (63 000 in 2024, 64 000 in 2025, 64 000 estimated for 2026): 2026-27 Estimates, Head 037 Department of Health, Controlling Officer's Report: https://www.budget.gov.hk/2026/eng/pdf/head037.pdf (retrieved 9 August 2026)
• The top five female cancers for ages 20–49, cervical cancer's 193 cases being 5.8% of that age group's 3,313 female cancers, and the top-five lists for the other age groups: Hong Kong Cancer Registry, Overview of Hong Kong Cancer Statistics of 2023 (August 2025): https://www3.ha.org.hk/cancereg/pdf/overview/Overview%20of%20HK%20Cancer%20Stat%202023.pdf (retrieved 9 August 2026)
• Maternal and Child Health Centre charges of $100/$205, the definition of eligible persons, the booking hotline, no screening needed for those who never had sexual experience or have had a total hysterectomy, seeking care for abnormal bleeding or discharge, and the practical rules before the examination: Department of Health Family Health Service, "Cervical Screening Service" (page states content revised 05/2026): https://www.fhs.gov.hk/english/main_ser/cs_service.html (retrieved 9 August 2026)
• Family Planning Association charges (cytology $350, co-testing $870, women's health check $700/$1,220, consultation $220, nursing $80, nine-valent HPV vaccine $1,700 a dose), and the absence of any published price for HPV testing alone: The Family Planning Association of Hong Kong fee page: https://www.famplan.org.hk/en/our-services/clinic-services/women-health/cervical-screening-and-women-health-service/fee (retrieved 9 August 2026)
• Most of those screened not having the disease, the "Offers of screening are ad hoc" cell, and call and recall in organised programmes: WHO Regional Office for Europe, Screening programmes: a short guide (2020): https://iris.who.int/items/ba910aa7-3c5a-4cf4-97d8-b128ac712881 (retrieved 9 August 2026)
• Positive predictive value against prevalence (including "and the higher the NPV"), improvements in five-year survival being largely due to earlier diagnosis and overdiagnosis (with the preceding SEER 1950–1996 attribution and the following sentence on late-stage incidence), and lead-time bias: National Cancer Institute, Cancer Screening Overview (PDQ®) – Health Professional Version (page updated 16 October 2023): https://www.cancer.gov/about-cancer/screening/hp-screening-overview-pdq (retrieved 9 August 2026)
• The 90–70–90 targets, the elimination threshold of 4 per 100,000 (the page giving neither time unit nor standard population), and adoption by the World Health Assembly in August 2020: World Health Organization, Cervical cancer elimination initiative: https://www.who.int/initiatives/cervical-cancer-elimination-initiative (retrieved 9 August 2026)
• The threshold's time unit ("per year") and the Chinese sentence quoted, the threshold resting on incidence data from population-based cancer registries (section 9.2, paraphrased here rather than quoted), and the absence of any standard population in the whole document: World Health Organization, Global strategy to accelerate the elimination of cervical cancer as a public health problem, official Chinese version (ISBN 9789240048638, IRIS 10665/359004), item page https://iris.who.int/handle/10665/359004, full PDF (9789240048638-chi.pdf, 56 pages) https://iris.who.int/bitstreams/f08c4b42-6a23-4a56-91fb-4fe213903209/download (retrieved 9 August 2026)
• Australia's move to primary HPV testing on 1 December 2017, universal self-sampling from 1 July 2022, ages 25–74, the definition of self-sampling uptake (all valid HPV tests each quarter), and 1.2% rising to 26.9% with the subgroup figures (51.9%/53.9%/≤29.1%/33.5%): Sultana F, Smith M, Saville M, et al. (including staff of the Cervical Screening Section of the Australian Government Department of Health), Lancet Public Health 2026;11(2):e101-e110 (DOI 10.1016/S2468-2667(25)00304-4; PMID 41611360)
• The Australian "invited … every 5 years" programme description: Australian Government Department of Health, About the National Cervical Screening Program (the archived copy states a page update date of 13 March 2026), read through a Wayback Machine snapshot of 14 May 2026: https://web.archive.org/web/20260514171655/https://www.health.gov.au/our-work/national-cervical-screening-program/about-the-national-cervical-screening-program (retrieved 9 August 2026)
• The pre-transition Australian modelling predictions (31%/36% and 24%/29%), the comparator arm (cytology every two years for women aged 18 to 69), the full strategy (direct colposcopy referral for HPV 16/18, reflex cytology triage for other types), and the phrase "cohorts offered vaccination": Lew JB, Simms KT, Smith MA, et al. Lancet Public Health 2017;2(2):e96-e107 (DOI 10.1016/S2468-2667(17)30007-5; PMID 29253402)

This article was written from the sources listed above. It is about the system, the figures and the trade-offs; which method you should use, and when to start and stop, it does not answer — that is for a doctor to decide on your individual circumstances.

---

#Further reading

• Department of Health Cervical Screening Programme: cervicalscreening.gov.hk
• Department of Health Family Health Service cervical screening service: fhs.gov.hk
• On this platform: Seasonal influenza vaccination